Prab: CSV import

2025-02-15T11:06:07Z

CSV import

← Older revision		Revision as of 11:06, 15 February 2025
Line 1:		Line 1:
	~~'''Nemonoxacin''' is a novel non-fluorinated quinolone antibiotic, which is currently under development for~~ the ~~treatment of various bacterial infections, particularly those caused by [[Gram-positive bacteria]]. It is a broad-spectrum~~ antibiotic ~~that is effective against both Gram-positive and Gram-negative bacteria.~~		{{Short description\|An encyclopedia article about the antibiotic Nemonoxacin}}

	==~~Etymology~~==		==Nemonoxacin==
	~~The name "~~Nemonoxacin" is ~~derived from the Greek words "nemo" meaning "nobody" and "nox" meaning "night". This could possibly refer to the~~ antibiotic~~'s ability~~ to ~~eliminate~~ bacteria, ~~thus "nobody"~~ (~~no bacteria) "night" (darkness, or illness~~).		[[File:Nemonoxacin_structure.svg\|thumb\|right\|Chemical structure of Nemonoxacin]]
			'''Nemonoxacin''' is a non-fluorinated [[quinolone]] antibiotic that is used to treat a variety of bacterial infections. It is particularly effective against [[Gram-positive bacteria]], including [[methicillin-resistant Staphylococcus aureus]] (MRSA) and [[Streptococcus pneumoniae]].

	==Mechanism of Action==		==Mechanism of Action==
	Nemonoxacin works by inhibiting ~~the~~ bacterial ~~enzymes~~ [[DNA gyrase]] and [[topoisomerase IV]], ~~which~~ are ~~necessary~~ for bacterial DNA replication, transcription, repair, and recombination. ~~This results in~~ the death ~~of the bacteria~~.		Nemonoxacin works by inhibiting bacterial [[DNA gyrase]] and [[topoisomerase IV]], enzymes that are essential for bacterial DNA replication, transcription, repair, and recombination. By interfering with these enzymes, nemonoxacin prevents the bacteria from multiplying and ultimately leads to bacterial cell death.

	==~~Clinical Trials~~==		==Pharmacokinetics==
	Nemonoxacin has ~~undergone Phase II~~ and ~~III clinical trials~~ for ~~the treatment~~ of ~~community~~-acquired pneumonia and ~~diabetic foot~~ infections~~. The results of these trials have shown that Nemonoxacin is as effective as other quinolone antibiotics, but with fewer side effects.~~		Nemonoxacin is administered orally and is well absorbed from the gastrointestinal tract. It has a high bioavailability and is widely distributed throughout the body. The drug is primarily excreted unchanged in the urine, which makes it effective for treating urinary tract infections.

			==Clinical Uses==
			Nemonoxacin is used to treat a variety of infections, including:
			* [[Community-acquired pneumonia]]
			* [[Skin and soft tissue infections]]
			* [[Urinary tract infections]]

	==Side Effects==		==Side Effects==
	~~The most common~~ side effects of ~~Nemonoxacin~~ include nausea, vomiting, diarrhea, and ~~abdominal pain~~. ~~Less common side effects include headache~~, ~~dizziness~~, and ~~rash~~.		Common side effects of nemonoxacin include [[nausea]], [[vomiting]], [[diarrhea]], and [[headache]]. Like other quinolones, it may also cause [[tendinitis]] and [[tendon rupture]], particularly in older adults and those taking corticosteroids.

	==~~Resistance~~==		==Development and Approval==
	~~Resistance to~~ Nemonoxacin is ~~less common than resistance to~~ other ~~quinolone antibiotics. This is due to the fact that Nemonoxacin is a non-fluorinated quinolone, which makes it less likely~~ to ~~be affected by bacterial resistance mechanisms~~.		Nemonoxacin was developed by [[TaiGen Biotechnology]] and has been approved for use in several countries, including [[Taiwan]] and [[China]]. It is currently undergoing clinical trials in other regions to expand its availability.

	==Related ~~Terms~~==		==Related pages==
			* [[Antibiotic]]
	* [[Quinolone]]		* [[Quinolone]]
	* [[~~Antibiotic]]~~		* [[Bacterial infection]]
	* [[Gram-positive bacteria]]
	* [[Gram-negative bacteria]]
	* [[DNA gyrase]]
	* [[Topoisomerase IV]]

	[[Category:Antibiotics]]		[[Category:Antibiotics]]
	[[Category:Quinolones]]		[[Category:Quinolones]]
	~~[[Category:Gram-positive bacteria]]~~
	~~[[Category:Gram-negative bacteria]]~~

	~~{{stub}}~~

Prab: CSV import

2024-02-20T00:16:59Z

CSV import

New page

'''Nemonoxacin''' is a novel non-fluorinated quinolone antibiotic, which is currently under development for the treatment of various bacterial infections, particularly those caused by [[Gram-positive bacteria]]. It is a broad-spectrum antibiotic that is effective against both Gram-positive and Gram-negative bacteria.

==Etymology==
The name "Nemonoxacin" is derived from the Greek words "nemo" meaning "nobody" and "nox" meaning "night". This could possibly refer to the antibiotic's ability to eliminate bacteria, thus "nobody" (no bacteria) "night" (darkness, or illness).

==Mechanism of Action==
Nemonoxacin works by inhibiting the bacterial enzymes [[DNA gyrase]] and [[topoisomerase IV]], which are necessary for bacterial DNA replication, transcription, repair, and recombination. This results in the death of the bacteria.

==Clinical Trials==
Nemonoxacin has undergone Phase II and III clinical trials for the treatment of community-acquired pneumonia and diabetic foot infections. The results of these trials have shown that Nemonoxacin is as effective as other quinolone antibiotics, but with fewer side effects.

==Side Effects==
The most common side effects of Nemonoxacin include nausea, vomiting, diarrhea, and abdominal pain. Less common side effects include headache, dizziness, and rash.

==Resistance==
Resistance to Nemonoxacin is less common than resistance to other quinolone antibiotics. This is due to the fact that Nemonoxacin is a non-fluorinated quinolone, which makes it less likely to be affected by bacterial resistance mechanisms.

==Related Terms==
* [[Quinolone]]
* [[Antibiotic]]
* [[Gram-positive bacteria]]
* [[Gram-negative bacteria]]
* [[DNA gyrase]]
* [[Topoisomerase IV]]

[[Category:Antibiotics]]
[[Category:Quinolones]]
[[Category:Gram-positive bacteria]]
[[Category:Gram-negative bacteria]]

{{stub}}

Nemonoxacin - Revision history

Prab: CSV import

Prab: CSV import